DK3024458T3 - USE OF FLECAINID AS AN ANTI-CONNEXIN AGENT AND PROCEDURE FOR POTENSEING THE EFFECTS OF A PSYCHOTROTOPIC MEDICINE - Google Patents

USE OF FLECAINID AS AN ANTI-CONNEXIN AGENT AND PROCEDURE FOR POTENSEING THE EFFECTS OF A PSYCHOTROTOPIC MEDICINE Download PDF

Info

Publication number
DK3024458T3
DK3024458T3 DK14742249.7T DK14742249T DK3024458T3 DK 3024458 T3 DK3024458 T3 DK 3024458T3 DK 14742249 T DK14742249 T DK 14742249T DK 3024458 T3 DK3024458 T3 DK 3024458T3
Authority
DK
Denmark
Prior art keywords
leu
val
ser
gly
ala
Prior art date
Application number
DK14742249.7T
Other languages
Danish (da)
English (en)
Inventor
Mathieu Charveriat
Franck Mouthon
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Application granted granted Critical
Publication of DK3024458T3 publication Critical patent/DK3024458T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
DK14742249.7T 2013-07-24 2014-07-24 USE OF FLECAINID AS AN ANTI-CONNEXIN AGENT AND PROCEDURE FOR POTENSEING THE EFFECTS OF A PSYCHOTROTOPIC MEDICINE DK3024458T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306074 2013-07-24
PCT/EP2014/065975 WO2015011246A1 (en) 2013-07-24 2014-07-24 Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug

Publications (1)

Publication Number Publication Date
DK3024458T3 true DK3024458T3 (en) 2018-02-19

Family

ID=48900920

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14742249.7T DK3024458T3 (en) 2013-07-24 2014-07-24 USE OF FLECAINID AS AN ANTI-CONNEXIN AGENT AND PROCEDURE FOR POTENSEING THE EFFECTS OF A PSYCHOTROTOPIC MEDICINE

Country Status (20)

Country Link
US (3) US9750734B2 (enExample)
EP (2) EP3308785A3 (enExample)
JP (3) JP6192830B2 (enExample)
KR (2) KR20170068629A (enExample)
CN (1) CN105579041B (enExample)
AU (1) AU2014295030B2 (enExample)
BR (1) BR112016001446A8 (enExample)
CA (2) CA2919140C (enExample)
DK (1) DK3024458T3 (enExample)
ES (1) ES2661647T3 (enExample)
HR (1) HRP20180487T1 (enExample)
HU (1) HUE037122T2 (enExample)
IL (2) IL243746A (enExample)
MX (2) MX365782B (enExample)
PL (1) PL3024458T3 (enExample)
PT (1) PT3024458T (enExample)
RU (2) RU2661026C2 (enExample)
TR (1) TR201802302T4 (enExample)
WO (1) WO2015011246A1 (enExample)
ZA (1) ZA201601146B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009472A1 (en) * 2015-07-15 2017-01-19 Theranexus Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
EP3781128A4 (en) * 2018-04-16 2022-03-09 Alsar Ltd Partnership COMPOSITIONS AND METHODS FOR THE EXTENDED RELEASE OF FLECAINIDE
US12529704B2 (en) 2018-06-11 2026-01-20 Indiana University Research And Technology Corporation Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
EP3593822A1 (en) 2018-07-13 2020-01-15 Theranexus Therapeutic and diagnostic applications of a new method of monitoring of neuroglial interaction memri)
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11021410B2 (en) * 2018-12-10 2021-06-01 Purdue Research Foundation Layer-wise agglomerated urea granules
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US20220265666A1 (en) * 2019-08-02 2022-08-25 Praxis Precision Medicines, Inc. Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression
CN111018694A (zh) * 2019-12-12 2020-04-17 贵州省欣紫鸿药用辅料有限公司 一种氟卡尼的生产方法
AU2021270308A1 (en) * 2020-05-13 2022-12-15 Akouos, Inc. Compositions and methods for treating GJB2-associated hearing loss
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
WO2022170081A1 (en) * 2021-02-05 2022-08-11 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001253825A (ja) 2000-03-13 2001-09-18 Masahiko Ichimada 帯状疱疹後神経痛用鎮痛剤
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
AU2006318447A1 (en) 2005-11-21 2007-05-31 The Board Of Trustees Of The University Of Alabama For And On Behalf Of The University Of Alabama Methods of using small molecule compounds for neuroprotection
KR20100027091A (ko) * 2006-11-15 2010-03-10 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
FR2935611B1 (fr) * 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20130184462A1 (en) 2010-09-30 2013-07-18 Council Of Scientific & Industrial Research Method for predicting and modeling anti-psychotic activity using virtual screening model
US20130096067A1 (en) 2011-09-14 2013-04-18 Norbert Perrimon Drosophila tumor stem cell model and uses thereof
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor

Also Published As

Publication number Publication date
PL3024458T3 (pl) 2018-08-31
KR101754045B1 (ko) 2017-07-05
RU2016105971A (ru) 2017-08-25
CN105579041B (zh) 2019-04-19
US20180028519A1 (en) 2018-02-01
US20160158213A1 (en) 2016-06-09
IL254210A0 (en) 2017-10-31
TR201802302T4 (tr) 2018-03-21
HUE037122T2 (hu) 2018-08-28
PT3024458T (pt) 2018-04-11
JP6694497B2 (ja) 2020-05-13
CA2997282A1 (en) 2015-01-29
EP3308785A2 (en) 2018-04-18
IL243746A0 (en) 2016-04-21
RU2018122564A (ru) 2019-03-06
US10639301B2 (en) 2020-05-05
ES2661647T3 (es) 2018-04-02
CA2919140C (en) 2018-05-01
US20190008844A1 (en) 2019-01-10
BR112016001446A2 (pt) 2017-08-29
MX2019006878A (es) 2019-08-01
ZA201601146B (en) 2017-11-29
WO2015011246A1 (en) 2015-01-29
JP2017119710A (ja) 2017-07-06
EP3024458B1 (en) 2018-01-03
IL254210B (en) 2021-10-31
EP3024458A1 (en) 2016-06-01
JP6192830B2 (ja) 2017-09-06
IL243746A (en) 2017-09-28
KR20170068629A (ko) 2017-06-19
CA2919140A1 (en) 2015-01-29
BR112016001446A8 (pt) 2018-01-23
RU2661026C2 (ru) 2018-07-11
HRP20180487T1 (hr) 2018-05-04
EP3308785A3 (en) 2018-07-18
JP2016525140A (ja) 2016-08-22
KR20160058760A (ko) 2016-05-25
MX2016001049A (es) 2016-08-12
CN105579041A (zh) 2016-05-11
MX365782B (es) 2019-06-13
JP2019059773A (ja) 2019-04-18
US9750734B2 (en) 2017-09-05
JP6453931B2 (ja) 2019-01-16
AU2014295030B2 (en) 2017-06-01
AU2014295030A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
DK3024458T3 (en) USE OF FLECAINID AS AN ANTI-CONNEXIN AGENT AND PROCEDURE FOR POTENSEING THE EFFECTS OF A PSYCHOTROTOPIC MEDICINE
JP5595268B2 (ja) メタボリックシンドローム、2型糖尿病、肥満又は糖尿病前症の治療的処置方法
JP2016525140A5 (enExample)
EP2633868A1 (en) Combination of alpha 7 nicotinic agonists and antipsychotics
JP2021506813A (ja) 神経筋障害の治療のためのフェノキシ酸
Tizzano et al. The Triple Uptake Inhibitor (1 R, 5 S)-(+)-1-(3, 4-Dichlorophenyl)-3-azabicyclo [3.1. 0] Hexane Hydrochloride (DOV 21947) Reduces Body Weight and Plasma Triglycerides in Rodent Models of Diet-Induced Obesity
HK1225278B (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
HK1225278A1 (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
KR20060032633A (ko) 벤조디아제핀 수용체의 알파 3 서브유닛에 대한 선택성을갖는 화합물을 사용한 중추신경계 장애의 치료 또는 예방방법
WO2014005720A1 (en) Use of (r)-phenylpiracetam for the treatment of disease-associated fatigue
WO2014005721A1 (en) Use of (r)-phenylpiracetam for the treatment of parkinson's disease
US20080200556A1 (en) Amine Compounds And Inhibiting Neurotrasmitter Reuptake
EP2891491A1 (en) Use of (r)-phenylpiracetam for the treatment of sleep disorders
Conley et al. Effect of the β3 adrenoceptor agonist CL 316243 on hypothalamic 5-HT synthesis and suppression of REM sleep in the rat
Carvelli β-Phenylethylamine Requires the Dopamine Transporter to Release Dopamine in Caenorhabditis elegans
Nandhakumar An Investigation into the Role of Insulin in Pain Threshold
Shumway et al. Neuroleptic Refusal by Involuntary
HK1079117B (en) Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament